The Symplicity renal denervation system is not approved by the U.S. Food and Drug Administration (FDA) for commercial distribution in the United States.
Biotech has always relied on partnerships with big pharmaceutical firms to share costs associated with Food and Drug Administration approval and eventually with marketing and distribution of approved drugs.